Back to Journals » Lung Cancer: Targets and Therapy » Volume 9

Hypersensitivity in ALK-positive lung cancers exposed to ALK inhibitors: a case of successful switch to an alternative ALK inhibitor and systematic review of the literature

Authors Deng L, Sharma J, Ravera E, Halmos B, Cheng H

Received 12 May 2018

Accepted for publication 27 July 2018

Published 6 September 2018 Volume 2018:9 Pages 73—77

DOI https://doi.org/10.2147/LCTT.S173948

Checked for plagiarism Yes

Review by Single-blind

Peer reviewers approved by Ms Justinn Cochran

Peer reviewer comments 3

Editor who approved publication: Dr Sai-Hong Ignatius Ou


Lei Deng,1 Janaki Sharma,2 Elizabeth Ravera,2 Balazs Halmos,2 Haiying Cheng2

1Department of Medicine, Jacobi Medical Center/Albert Einstein College of Medicine, Bronx, NY, USA; 2Department of Oncology, Montefiore Medical Center/Albert Einstein College of Medicine, Bronx, NY, USA

Abstract: Alectinib can cause rare, but severe hypersensitivity. The cross-reactivity between different ALK inhibitors is unknown and desensitization is the only reported management. We hereby report the first case of severe delayed hypersensitivity developed in a lung cancer patient treated by alectinib, who was successfully managed by switching to brigatinib, another ALK inhibitor. The patient achieved excellent anti-tumor response to brigatinib. Our case provides an alternative and safe strategy in patients with alectinib-related hypersensitivity.

Keywords: alectinib, brigatinib

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]